Lit Matters 2: Apixaban > Rivaroxaban for VTEs

Untreated deep vein thrombosis and pulmonary embolism carry a substantial recurrence risk, and direct oral anticoagulants are now standard therapy for many patients with acute VTE. In a large real-world comparison, apixaban was associated with fewer recurrent VTEs and fewer major bleeding admissions than rivaroxaban.

Apixaban vs Rivaroxaban for VTE

• Large real-world comparison: A propensity-matched insurance database study compared roughly 18,000 patients per arm, giving this apixaban-versus-rivaroxaban question more power than earlier small observational studies.
• Recurrent VTE signal: Apixaban showed lower recurrent venous thromboembolism rates than rivaroxaban, with event rates of 8.9 versus 11.4 per 100 person-years.
• Bleeding outcome advantage: Major bleeding severe enough for admission, specifically GI bleed or intracranial hemorrhage, was also lower with apixaban at 7.2 versus 11.0 events per 100 person-years.
• Prior trial context: Head-to-head randomized data are still pending, but prior pivotal trials already suggested apixaban has a bleeding edge over warfarin while rivaroxaban was more bleeding-neutral by comparison.
• Practice-changing takeaway: For a new VTE when both DOACs are reasonable options, apixaban currently looks like the stronger default on effectiveness and safety. We get into how much this should change prescribing in the episode.
• Cost and access reality: Drug cost still matters: DOAC therapy may run about $550 per month versus roughly $11 for warfarin, so affordability can outweigh marginal outcome differences in real practice.